SRPT | tickerfilter.com

Fundamental analysis

43%

Profitability 25%

Dept financing 31%

Liquidity 75%

Performance 55%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.40%

1 Month

-3.62%

3 Months

-46.72%

6 Months

-52.76%

1 Year

-52.24%

2 Year

-50.84%

Key data

Stock price

$61.51

P/E Ratio

49.37

DAY RANGE

$60.18 - $62.47

EPS

-$0.42

52 WEEK RANGE

$48.01 - $173.00

52 WEEK CHANGE

-$51.44

MARKET CAP

11.614 B

YIELD

N/A

SHARES OUTSTANDING

95.366 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-30-2025

BETA

1.32

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,656,250

AVERAGE 30 VOLUME

$2,853,081

Company detail

CEO: Douglas S. Ingram
Region: US
Website: sarepta.com
Employees: 840
IPO year: 1997

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio.

SRPT - Sarepta Therapeutics, Inc.